Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

Last updated: September 4, 2024
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

4

Condition

Essential Tremor

Treatment

Dexmedetomidine

Clinical Study ID

NCT04730609
20-004712
  • Ages > 18
  • Female

Study Summary

The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women presenting for planned cesarean delivery.

  • American Society of Anesthesiology Physical Classification Status 2 or 3; withoutmajor medical co-morbidities.

  • Singleton gestation in the 3rd trimester (28-42 weeks gestation).

  • Spinal anesthesia technique Women presenting for planned cesarean delivery.

  • American Society of Anesthesiology Physical Classification Status 2 or 3; withoutmajor medical co-morbidities.

  • Singleton gestation in the 3rd trimester (28-42 weeks gestation).

  • Spinal anesthesia technique.

Exclusion

Exclusion Criteria:

  • Any contraindication to spinal anesthesia technique.

  • Allergy or intolerance to dexmedetomidine or clonidine.

  • Oral temperature < 36° Celsius prior to procedure.

  • Unable to give personal consent.

  • PPROM or concern for infection (e.g., chorioamnionitis).

  • Conversion to General Anesthesia prior to randomization.

  • Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide)administered prior to randomization.

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Dexmedetomidine
Phase: 4
Study Start date:
September 21, 2021
Estimated Completion Date:
August 31, 2025

Study Description

Potential subjects will consist of parturients who present for scheduled elective cesarean deliveries. Patients will be recruited and consented for the study pre-operatively and if they display Grade 3 or 4 shivering at the time of delivery then they will be enrolled in the study. Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect - cessation of shivering within 5 minutes of medication administration. An anesthesia physician not involved in patient care or assessment will prepare the dexmedetomidine for intravenous use. Anesthesia will be initiated with spinal anesthesia with our institution's typical dosing of 1.6 mL 0.75% bupivacaine with dextrose, 15 mcg fentanyl, and 150 mcg morphine.

Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan. Members of the anesthesia team caring for women in the study will be educated on the grading scales.

  • Grade 0: no shivering;

  • Grade 1: one or more of the following: piloerection, peripheral vasoconstriction, peripheral cyanosis, but without visible muscle activity; Grade 2: visible muscle activity confined to one muscle group;

  • Grade 3: visible muscle activity in more than one muscle group;

  • Grade 4: gross muscle activity involving the whole body

Connect with a study center

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.